Varicella Vaccination

Diaz P.S. Au D. , & Smith S. (1991). Lack of transmission of the live attenuated varicella vaccine virus to immunocompromised children after immunization of their siblings. Pediatrics, 87, 166–170.

Holmes S.J. Reef S. Hadler S.C. Williams W.H. , & Wharton M. (1996). Prevention of varicella: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report, 45, 1–36.

Lieu T.A. Cochi S.L. Black S.B. Shinefield H.R. Holmes S.J. Wharton M. Washington P.E. , (1994). Cost effectiveness of a routine varicella program for U.S. children. JAMA, 271, 375–381.

Lund J. (1993). Varicella zoster virus in the health care setting: Risk and management. AAOHN Journal, 41, 369–373.

Merck & Co., Inc. (1995). Varivax (varicella virus vaccine live Oka/Merck) (Product Monograph). West Point, PA: Merck & Co, Inc. 1–35.

Merck & Co., Inc. (1996). Chickenpox. Now you see them … Now you won't. (Provider Packet). West Point, PA: Merck & Co, Inc. 1–14.

Tsolia M. Gershon A.A. Steinberg S.P. (1990). Live attenuated varicella vaccine: Evidence that the virus is attenuated and the importance of skin lesions in transmission of varicella zoster virus. The Journal of Pediatrics, 116, 184–190.

Weber D.J. Rutala W.A. , & Parham C. (1988). Impact and costs of varicella prevention in a university hospital. American Journal of Public Health, 78, 19–21.